MTEM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases...

Stats
Today's Volume	68 803.00
Average Volume	64 717.00
Market Cap	9.16M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.970 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.950
ATR14	$0.0340 (1.99%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Biotech Target N V	Buy	250 000	Common Stock
2024-04-02	Biotech Target N V	Buy	769 334	Common Warrants (right to buy)
2024-04-02	Biotech Target N V	Buy	134 667	Prefunded Warrants (right to buy)
2024-04-02	Lalande Kevin M.	Buy	1 154 154	Warrants (Right to Buy)
2024-04-02	Lalande Kevin M.	Buy	402 077	Pre-Funded Warrants (Right to Buy)

INSIDER POWER
99.93
Last 98 transactions
Buy: 16 322 736 \| Sell: 222 785

Volume Correlation

Long: 0.05 (neutral)

Short: -0.85 (strong negative)

Signal:(61.69) Neutral

Molecular Templates Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Molecular Templates Inc Correlation - Currency/Commodity

-0.29
( neutral )

-0.38
( neutral )

0.00
( neutral )

-0.32
( neutral )

0.40
( neutral )

0.27
( neutral )

Molecular Templates Inc Financials

Annual	2023
Revenue:	$57.31M
Gross Profit:	$50.40M (87.94 %)
EPS:	$-1.800

FY	2023
Revenue:	$57.31M
Gross Profit:	$50.40M (87.94 %)
EPS:	$-1.800

FY	2022
Revenue:	$19.75M
Gross Profit:	$11.95M (60.51 %)
EPS:	$-24.69

FY	2021
Revenue:	$38.70M
Gross Profit:	$0.00 (0.00 %)
EPS:	$1.690

Financial Reports:

No articles found.

Molecular Templates Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.